GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Loans Receivable

ANVS (Annovis Bio) Loans Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Loans Receivable?

Annovis Bio's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Annovis Bio Loans Receivable Historical Data

The historical data trend for Annovis Bio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Loans Receivable Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

Annovis Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Annovis Bio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Annovis Bio Loans Receivable Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio Business Description

Traded in Other Exchanges
Address
101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831